The Medical Letter on Drugs and Therapeutics
Namzaric - A Combination of 2 Old Drugs for Alzheimer's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Namzaric (Forest), a fixed-dose combination of extended-release (ER) memantine (Namenda XR), an NMDA-receptor antagonist, and donepezil (Aricept, and generics), an acetylcholinesterase inhibitor, for treatment of moderate to severe Alzheimer's type dementia in patients previously stabilized on both drugs. The patent for Namenda has recently expired and generic formulations of memantine 5- and 10-mg tablets have been approved.

STANDARD TREATMENT — Acetylcholinesterase inhibitors and memantine are the only drugs currently available for treatment of Alzheimer's disease (AD). They have produced modest but apparently persistent improvements in cognition, activities of daily living, and behavior. None of these agents have been shown to stop or reverse the underlying neurodegenerative process.1

Many patients with moderate ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Namzaric - A Combination of 2 Old Drugs for Alzheimer's Disease
Article code: 1473c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian